Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: External validation

CardioVascular and Interventional Radiology

Volumn 35, Issue 5, 2012, Pages 1102-1108

  Guiu, Boris ^a,b   Deschamps, Frédéric ^a   Boulin, Mathieu ^b   Boige, Valérie ^a   Malka, David ^a   Ducreux, Michel ^a   Hillon, Patrick ^b   De Baère, Thierry ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Chemoembolization; Cirrhosis; Liver cancer; Predictor; Survival

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; GAMMA GLUTAMYLTRANSFERASE; IODINATED POPPYSEED OIL;

AGED; ARTICLE; CANCER PROGNOSIS; CHEMOEMBOLIZATION; DRUG ELUTING BEAD; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; IMPLANT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SURVIVAL PREDICTION; TIME TO TREATMENT FAILURE; TREATMENT FAILURE; TUMOR VOLUME;

AGED; BIOPSY; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84867580707     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-011-0293-9     Document Type: Article

References (23)

1. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208-1236
2. Camma C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224(1):47-54
3. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429-442
4. Llovet JM, Real MI, Montana X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734-1739
5. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164-1171
6. Doffoel M, Bonnetain F, Bouche O et al (2008) Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402). Eur J Cancer 44(4):528-538
7. Ikeda Y, Taniguchi N (2005) Gene expression of gamma- glutamyltranspeptidase. Methods Enzymol 401:408-425
8. Zhang JB, Chen Y, Zhang B et al (2011) Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol 23:787-793
9. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxi A, Camma C (2010) A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51(4):1274-1283
10. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25-34
11. Cui J, de Klerk N, Abramson M et al (2009) Fractional polynomials and model selection in generalized estimating equations analysis, with an application to a longitudinal epidemiologic study in Australia. Am J Epidemiol 169(1):113-121
12. Whitfield JB (2001) Gamma glutamyl transferase. Crit Rev Clin Lab Sci 38(4):263-355
13. Vickers AJ (2011) Prediction models: revolutionary in principle, but do they do more good than harm? J Clin Oncol 29(22):2951-2952
14. Brown DB, Gould JE, Gervais DA et al (2009) Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 20(7 Suppl):S425-S434
15. Ruhl CE, Everhart JE (2009) Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 136(2):477-485 e411
16. Strasak AM, Pfeiffer RM, Klenk J et al (2008) Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women. Int J Cancer 123(8):1902-1906
17. Strasak AM, Rapp K, Brant LJ et al (2008) Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study. Cancer Res 68(10):3970-3977
18. Poynard T, Zourabichvili O, Hilpert G et al (1984) Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 4(2):324-327
19. Hanigan MH (1998) gamma-Glutamyl transpeptidase, a glutathionase: its expression and function in carcinogenesis. Chem Biol Interact 111-112:333-342
20. Hanigan MH, Frierson HF Jr, Swanson PE, De Young BR (1999) Altered expression of gamma-glutamyl transpeptidase in human tumors. Hum Pathol 30(3):300-305
21. Hanigan MH, Gallagher BC, Townsend DM, Gabarra V (1999) Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis 20(4):553-559
22. Hanigan MH, Pitot HC (1985) Gamma-glutamyl transpeptidaseits role in hepatocarcinogenesis. Carcinogenesis 6(2):165-172
23. Efron B, Tibshirani RJ (1993) An introduction to the Bootstrap (Monographs on Statistics and Applied Probability). Chapman & Hall/CRC, London